INTECH Investment Management’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$44.3K Buy
31,607
+3,507
+12% +$5.73K ﹤0.01% 2069
2026
Q1
$47.5K Sell
28,100
-19,961
-42% -$35.4K ﹤0.01% 2008
2025
Q4
$68.2K Hold
48,061
– – ﹤0.01% 2231
2025
Q3
$78.8K Sell
48,061
-2,016
-4% -$2.24K ﹤0.01% 2314
2025
Q2
$36.6K Sell
50,077
-43,642
-47% -$37.7K ﹤0.01% 2436
2025
Q1
$75.6K Buy
93,719
+66,119
+240% +$76.1K ﹤0.01% 2373
2024
Q4
$38.1K Buy
+27,600
New +$31K ﹤0.01% 2352

Other funds holding CHRS

INTECH Investment Management's CHRS Position: Q2 2026 in Review

INTECH Investment Management increased its Coherus Oncology (CHRS) stake by 12% in Q2 2026, buying an estimated $5.73K and bringing the position to 31,607 shares worth $44.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2069.

INTECH Investment Management first reported a position in CHRS in Q4 2024 and has held it in 7 quarters since. The position peaked at $78.8K in Q3 2025. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • INTECH Investment Management held 31,607 shares of Coherus Oncology worth $44.3K as of Q2 2026.
  • INTECH Investment Management bought 3,507 Coherus Oncology shares in Q2 2026, an estimated $5.73K.
  • Coherus Oncology made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #2069 holding.
  • INTECH Investment Management first reported a position in Coherus Oncology in Q4 2024 and has held it in 7 quarters since.
  • INTECH Investment Management's Coherus Oncology position peaked at $78.8K in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.